Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
33
resultados
Última actualización
15/06/2025 [07:38:00]
Resultados 25 a 33 de 33
Resumen de: US2025188545A1
Provided herein are methods of predicting the responsiveness of a lymphoma patient to a cancer treatment comprising clustering patients into subgroups of patients using gene expression levels. Also provided herein are methods of treating a lymphoma patient based on predicting the responsiveness of the lymphoma patient to a cancer treatment.
Resumen de: WO2024028433A1
Inventors have first investigated the impact of PIK3CA inhibition in NZBWF1/J mice a model of lymphoproliferative disorders. They randomly assigned 30 females aged of 24 weeks to receive either vehicle (n=15) or alpelisib (n=15) during 4 weeks. At the time of sacrifice, alpelisib treated mice demonstrated significantly reduced spleen size. Flow cytometry analysis revealed that B cells were significantly reduced in alpelisib treated mice and CD8 cells count corrected. They then decided to explore the relevance of alpelisib in MRL/MpJ-Faslpr/J mice (referred here as MRL-lpr), another mouse model of lymphoproliferative disorder. These mice with homozygous Fas mutation usually develop severe lymphadenoproliferation. At the time of sacrifice, MRL-lpr mice treated with alpelisib demonstrated a reduction on their spleen and lymph node sizes. Flow cytometry analysis showed correction of B cells, T cells and other immune cells in peripheral blood mononuclear cells (PBMC), lymph nodes and spleen. The invention relates to a method for treating lymphoproliferative disorder in a subject in need thereof comprising a step of administering the subject with a therapeutically effective amount of a PIK3CA inhibitor.
Resumen de: WO2024030569A1
A novel human T-cell acute lymphoblastic leukemia (T-ALL) cell line called INB16 (ATCC Deposit no. PTA-125809) induces memory like function on natural killer cells upon contact therewith, which memory like natural killer cells have demonstrated ability to identify and kill cancer cells, including hematologic and solid tumor cells. Useful applications of the INB16 cell line include research, a cancer therapeutic agent comprising replication incompetent INB16 cells and/or membrane portions thereof for in vivo administration and restoring function of a patient's own NK cells, and related methods of treating cancer.
Resumen de: US2025177529A1
Patients with relapsing or refractory cancer have limited treatment options because the knowledge or presence of tumor-associated antigens is lacking. The proposed therapy mounts an antigen-independent anticancer response in a rapid, safe, and targeted manner due to its ability to stimulate innate immune cells in solid tumors, addressing a major, unmet major need in clinical oncology. A holistic system is disclosed capable of preparing and purifying cell samples for adoptive transfer into patients suffering from relapsing and refractory lymphomas and other solid cancers. An acoustofluidic device processes clinically relevant cell samples in a plug-and-play format, offering cell preparation speeds >100× faster than conventional CAR T-cell therapy.
Resumen de: US2025179132A1
The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (APCs) such as dendritic cells, or APC precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or APC.
Resumen de: US2025179469A1
The present disclosure provides improved genome editing compositions and methods for editing a casitas B-lineage (Cbl) lymphoma proto-oncogene B (CBLB) gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
Resumen de: WO2025114669A1
The present invention relates to a method for the in vitro or ex vivo diagnosis of the survival outcomes of a patient suffering from acute myeloid leukemia (AML), comprising a step of detecting the expression of at least newly identified AML biomarker genes.
Resumen de: WO2025114919A1
The present disclosure relates to methods for treating or preventing a leukemia or a myelodysplastic syndrome in a subject in need thereof, said method comprising administering to the subject an effective amount of a combination comprising: (i) a binding protein comprising a first antigen binding domain (ABD) with binding specificity to CD123 and a second (ABD) with binding specificity to NKp46; and one or both of: (ii) a BCL-2 inhibitor, and (iii) a DNA hypomethylating agent.
Resumen de: AU2025203436A1
Abstract The present disclosure provides anti-CD19 antibodies and venetoclax for use in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or small lymphocytic lymphoma. The anti-CD19 antibodies, in particular MOR00208, and venetoclax are administered to patients suffering non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and/or small lymphocytic lymphoma (SLL) according to a specific treatment paradigm to mitigate therapy associated tumor lysis syndrome.
Resumen de: WO2025117764A1
Methods of treating multiple myeloma by administering a bispecific antibody that binds to CD3 and BCMA to a patient in need are provided.
Resumen de: WO2025117672A1
The invention provides indazolyl-piperidine sulfonamide and related compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condition, such as a proliferative disorder, inflammatory disorder, or autoimmune disorder.
Resumen de: WO2025116570A1
The present invention relates to: a recombinant polypeptide specifically binding to B cells; and a composition for preventing or treating B cell lymphoma, comprising same as an active ingredient. The present invention can significantly improve direct killing activity against tumor cells by conjugating concanavalin A, which is a ligand of MPZL1, to an antibody molecule that recognizes a B cell-specific antigen such as CD20. Therefore, unlike therapeutic antibodies having main mechanisms of antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated phagocytosis (ADP), the recombinant polypeptide of the present invention does not depend on operating mechanisms of patient immune systems, and thus can be effectively used in an effective therapeutic composition even for cancer patients with reduced immune activity.
Resumen de: US2025177395A1
The compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin
Resumen de: US2025177394A1
The invention provides inter alia methods of treating cancer comprising administering to a subject a cytidine triphosphate synthase 1 (CTPS1) inhibitor and a B-cell lymphoma 2 (BCL2) inhibitor.
Resumen de: US2025179188A1
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
Resumen de: US2025177519A1
The present disclosure provides methods for treating multiple myeloma comprising administering an anti-CD38 antibody and an Interleukin-2 analog to an individual in need thereof and optionally administering Natural Killer (NK) cells having expression of CD38 reduced or knocked-out.
Resumen de: US2025177520A1
Methods of treating multiple myeloma by administering a bispecific antibody that binds to CD3 and BCMA to a patient in need are provided.
Resumen de: US2025177540A1
The present invention provides stable pharmaceutical compositions of pegylated carfilzomib compounds, methods for preparing the compositions, and uses of the compositions for treating cancer, including hematologic malignancies such as multiple myeloma. The compositions can be stored in frozen form or lyophilized to dry solid form.
Resumen de: WO2024054564A2
MicroOrganoSpheres (MOS) generated using cells from multiple myeloma bone marrow biopsies are provided herein, as are methods and materials for making and using such MOS.
Resumen de: WO2024026019A1
This disclosure relates to methods for treating cancer in a subject identified as having chronic myelomonocytic leukemia (CMML), comprising administering an anti-ILT3 antigen binding protein, or antigen binding fragment to the patient every three weeks (Q3W).
Resumen de: WO2024023313A1
The invention relates to genetically engineered mouse models for multiple myeloma (MM) and their uses thereof for the development of multiple myeloma models as well as for the screening of compounds suitable for the treatment of multiple myeloma.
Resumen de: CN118338900A
The present disclosure relates to compositions comprising nirogastat or a pharmaceutically acceptable salt thereof and methods of treatment.
Resumen de: NL2038217A
Disclosed is an application of chicken TRIM45 truncated recombinant protein or polyclonal antibody thereof. The invention discloses an application of chicken TRIM45 gene, recombinant vector, truncated recombinant protein or polyclonal antibody thereof in preparing anti-avian leukaemia virus related drugs, where the accession number of chicken TRIM45 gene Genbank is XM_0 70 7211. The truncated recombinant protein of chicken TRIM45 constructed by the invention avoids the defect of full-length expression stability, and meanwhile, the immune effect is more stable and the antibody level is higher. At the same time, the eukaryotic expression vector 10 and polyclonal antibody prepared by the invention can be applied to the research on the mechanism of chicken TRIM45' s regulation of ALV-J replication, which has far-reaching significance and makes up for the blank of chicken TRIM45 antibody preparation and research; It provides a new idea for the mechanism study of anti-ALV-J infection and immune regulation in chickens.
Resumen de: AU2023367741A1
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
Nº publicación: IL320528A 01/06/2025
Solicitante:
LEGEND BIOTECH USA INC [US]
JANSSEN BIOTECH INC [US]
LEGEND BIOTECH USA INC,
JANSSEN BIOTECH INC
Resumen de: TW202430551A
A method for assessing responsiveness of a subject to a treatment comprising T cells expressing a bivalent BCMA-targeting chimeric antigen receptor (CAR), comprising administering to the subject the T cells, and assessing the responsiveness of the subject to the treatment based on time length the subject maintains minimal residual disease (MRD) negative status.
BOPI
Sede Electrónica
